Navigation Links
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association

om non-clinical studies demonstrates that SNS-595 and cytarabine act synergistically to ablate bone marrow in experimental models while sparing normal hematopoietic recovery. Sunesis plans to initiate a Phase 1b clinical trial of SNS-595 in combination with cytarabine in patients with advanced acute leukemias in the third quarter of this year.

Non-clinical Results Compare CDK-Inhibitor SNS-032 to Flavopirodol

In a second presentation, Sunesis reported the results of studies evaluating its cyclin-dependent kinase (CDK)-inhibitor, SNS-032, which demonstrated that SNS-032 has greater selectivity and cellular potency to other CDK-targeting agents, such as flavopiridol and seliciclib. SNS-032 was analyzed against flavopiridol in a cancer cell line in bovine and human serum to assess mechanism of action and target modulation. SNS-032 was observed to be a more potent inhibitor of CDK9 and to possess greater pro-apoptotic activity than flavopiridol in human serum. In addition, mechanism-based, dose-dependent target modulation indicating CDK7 and CDK9 inhibition, as well as down-modulation of the survival signaling protein Mcl-1, was observed in peripheral blood cells obtained from patients treated with SNS-032 in a Phase 1 solid tumor clinical trial. These data further differentiate SNS-032 from flavopiridol.

"Results from these studies distinguish SNS-032 from other CDK inhibitors being tested in the clinic. Data presented on SNS-032 from comparative studies show this promising product candidate is hitting its molecular targets, including Mcl-1, in peripheral mononuclear cells taken from patients undergoing treatment in a dose-dependent fashion," said Dr. Adelman. "Our observations relating to SNS-032's mechanism support the ongoing Phase 1 clinical trial of SNS-032 in B-cell malignancies. This Phase 1 trial is designed to test our hypothesis that targeted inhibition of survival signaling in hematologic diseases will result in meaningful clinical benef
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... , April 21, 2015  The American ... U.S. Food and Drug Administration that the agency,s ... for the last 25 years to protect the ... homeopathic medicines. AAHP, the industry,s trade association, was ... of homeopathic medicines to engage in productive discussions ...
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... of amendments to its Clinical Trial Authorizations (CTAs) filed ... Regulatory Agency (MHRA) and Germany,s ... (BfArM) for the expansion of the Company,s global Phase ... hepatocellular carcinoma (primary liver cancer, or HCC), to include ...
Breaking Medicine Technology:Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4
... - First prospective biomarker trial in non-small cell ... /PRNewswire-FirstCall/ -- Response,Genetics, Inc. today announced that positive ... issue of the Journal of Clinical,Oncology suggests that ... in patient biopsies,with advanced non-small cell lung cancer ...
... LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Society for,Medical Oncology (ESMO) Conference, which is currently ... in two oral and,poster presentations on Sunday, July ...
Cached Medicine Technology:Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6
(Date:4/21/2015)... City, Utah (PRWEB) April 21, 2015 ... for small businesses, announced today the publication of a ... Recent health reform brought changes to the health insurance ... caused some business owners to question what is permitted ... eBook helps small business owners determine which HRAs are ...
(Date:4/21/2015)... 21, 2015 Le Petit Retreat Day Spa ... doors today in the leafy, historic Larchmont neighborhood, newly renamed ... a new theme of “Disconnect to Reconnect.” Tina Figueroa, ... the award-winning day spa, announces the new name and new ... Day offerings that help celebrate connections with Moms and their ...
(Date:4/21/2015)... Zane Benefits, a software company reinventing ... Rick Lindquist has been selected as one of Employee ... Rick Lindquist, “There is a massive shift taking place ... business solutions are at its forefront. Our entire team ... Adviser’s Rising Stars.” , According to the Census Bureau, ...
(Date:4/21/2015)... April 21, 2015 Carinsurancesavings.biz has released a ... under proper surveillance and explaining the impact on a ... vehicles safe and supervised may be eligible for advantageous auto ... in a simple and efficient way. This will also help ... convenient and simple way. , Finding low cost coverage is ...
(Date:4/21/2015)... 2015 Optimity Advisors ( Optimity), ... firm that helps clients in complex industries navigate ... the Association of Community Affiliated Plans ... represents 58 local, not-for-profit, community-affiliated Safety Net Health ... people primarily enrolled in public or state-sponsored coverage ...
Breaking Medicine News(10 mins):Health News:Larchmont Sanctuary Spa Revealed as New Name For Neighborhood Spa; New Owner, New Eco Offerings & New Theme: “Disconnect to Reconnect” 2Health News:Larchmont Sanctuary Spa Revealed as New Name For Neighborhood Spa; New Owner, New Eco Offerings & New Theme: “Disconnect to Reconnect” 3Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Auto Insurance Quotes Offer Excellent Security for A Car 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2
... and provides actionable advice to manage, report and monitor ... America(R) , a part of Experian and a leader ... its Red Flags Rule system designed to help hospitals ... Rule from the Federal Trade Commission (FTC). This advanced ...
... surgery, a new surgical approach to metabolic disease, ... some patients. This data was presented today ... 18th Annual Meeting & Clinical Congress.(Logo: ... just weight-loss surgery," Chief of Gastrointestinal Metabolic Surgery ...
... brief highlights critical components of university,s successful program MINNEAPOLIS, May ... management program will deliver a positive return on investment (ROI) ... Louisville knows this to be true and a new ... shows how this Louisville, Ky.-based university achieved a ROI of ...
... improves level of overall functioning and mental health ... a recent Finnish study. , Jorvi Early psychosis ... Central Hospital (HUCH), Jorvi Hospital, Finland, is a ... at risk of developing first-episode psychosis. As developing ...
... upper secondary school is a challenge for many young people. ... of school and higher education, upper secondary school is a ... secondary school pupils are at the greatest risk: up to ... a phenomenon to be taken seriously, as it can lead ...
... study of certified nursing assistants (CNAs) in nursing homes ... least one work-related injury in the previous year. One ... and nearly half of those without medical insurance claimed ... statistics, gathered from the first-ever National Nursing Assistant Survey ...
Cached Medicine News:Health News:SearchAmerica(R) Unveils Next-Generation Red Flags Rule System for Health Care 2Health News:SearchAmerica(R) Unveils Next-Generation Red Flags Rule System for Health Care 3Health News:SearchAmerica(R) Unveils Next-Generation Red Flags Rule System for Health Care 4Health News:Can New Surgery Revolutionize Diabetes Treatment? 2Health News:Can New Surgery Revolutionize Diabetes Treatment? 3Health News:University of Louisville Realizes Nearly 3:1 ROI with Employee Health Management 2Health News:Early and network-oriented care may help adolescents at risk of developing psychosis 2Health News:One in five girls in upper secondary school suffers from school burnout 2Health News:Nursing assistant workforce facing financial, health challenges 2
... CardioVad is a unique left ventricular assist device ... It is being used in a small group ... as part of an FDA-approved Feasibility Study. The ... the external power source for minutes or hours. ...
... has introduced the world's first minimally-invasive epicardial ... Epicardial Lead Implant Tool, which has been ... will expand the options available to implanting ... lead on the heart during pacemaker implants. ...
The Schiller treadmill ergometer is designed for stress tests, sports medicine and cardiology. It is equipped and tested with the latest safety system and has been manufactured under the stringent qu...
... Q-Stress Treadmill has digitally-controlled drive ... moving parts that can wear out. ... speed change mechanism, and fewer drive ... level of dependability. It can carry ...
Medicine Products: